The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The abrysvo or arexvy market's growth is expected to be significantly driven by the increasing prevalence of respiratory syncytial virus RSV infections. RSV infections primarily affect the ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Two other RSV vaccines – GSK's Arexvy and Moderna's mResvia – are approved for older adult use only. Abrysvo made $890 million in sales last year, but it's not clear what proportion of that ...

Abrysvo has also been approved as a maternal vaccine to prevent RSV in newborns, an indication that GSK abandoned for Arexvy, but in that category it has to compete with Sanofi and AstraZeneca’s ...

Shares were also aided by a successful US and European launch of Arexvy, a respiratory syncytial virus (RSV) vaccine for older adults. Although risks around the Zantac litigation remain a concern ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.